LISKOVA, A., M. SAMEC, L. KOKLESOVA, S. M. SAMUELSM, K. V. ZHAI, R. K. AL-ISHAQ, M. ABOTALEB, V. NOSAL, K. KAJO, M. ASHRAFIZADEH, A. ZARRABI, A. BROCKMUELLER, M. SHAKIBAEI, P. SABAKA, I. MOZOS, D. ULLRICH, Robert PROSECKÝ, G. LA ROCCA, M. CAPRNDA, D. BUSSELBERG, L. RODRIGO, Peter KRUŽLIAK and P. KUBATKA. Flavonoids against the SARS-CoV-2 induced inflammatory storm. BIOMEDICINE & PHARMACOTHERAPY. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, vol. 138, June 2021, p. 1-12. ISSN 0753-3322. Available from: https://dx.doi.org/10.1016/j.biopha.2021.111430.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Flavonoids against the SARS-CoV-2 induced inflammatory storm
Authors LISKOVA, A., M. SAMEC, L. KOKLESOVA (203 Czech Republic), S. M. SAMUELSM, K. V. ZHAI, R. K. AL-ISHAQ, M. ABOTALEB, V. NOSAL, K. KAJO, M. ASHRAFIZADEH, A. ZARRABI, A. BROCKMUELLER, M. SHAKIBAEI, P. SABAKA, I. MOZOS, D. ULLRICH, Robert PROSECKÝ (203 Czech Republic, belonging to the institution), G. LA ROCCA, M. CAPRNDA, D. BUSSELBERG, L. RODRIGO, Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution) and P. KUBATKA.
Edition BIOMEDICINE & PHARMACOTHERAPY, Paris, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, 0753-3322.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher France
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.419
RIV identification code RIV/00216224:14110/21:00123995
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.biopha.2021.111430
UT WoS 000641386500004
Keywords in English SARS-CoV-2; COVID-19; Inflammation; Cytokine storm; Phytochemicals; Flavonoids; Immunomodulation; Anti-inflammatory effects
Tags 14110116, 14110121, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 31/1/2022 10:08.
Abstract
The disease severity of COVID-19, especially in the elderly and patients with co-morbidities, is characterized by hypercytokinemia, an exaggerated immune response associated with an uncontrolled and excessive release of proinflammatory cytokine mediators (cytokine storm). Flavonoids, important secondary metabolites of plants, have long been studied as therapeutic interventions in inflammatory diseases due to their cytokine-modulatory effects. In this review, we discuss the potential role of flavonoids in the modulation of signaling pathways that are crucial for COVID-19 disease, particularly those related to inflammation and immunity. The immunomodulatory ability of flavonoids, carried out by the regulation of inflammatory mediators, the inhibition of endothelial activation, NLRP3 inflammasome, toll-like receptors (TLRs) or bromodomain containing protein 4 (BRD4), and the activation of the nuclear factor erythroid-derived 2-related factor 2 (Nrf2), might be beneficial in regulating the cytokine storm during SARS-CoV-2 infection. Moreover, the ability of flavonoids to inhibit dipeptidyl peptidase 4 (DPP4), neutralize 3-chymotrypsin-like protease (3CL(pro)) or to affect gut microbiota to maintain immune response, and the dual action of angiotensin-converting enzyme 2 (ACE-2) may potentially also be applied to the exaggerated inflammatory responses induced by SARS-CoV-2. Based on the previously proven effects of flavonoids in other diseases or on the basis of newly published studies associated with COVID-19 (bioinformatics, molecular docking), it is reasonable to assume positive effects of flavonoids on inflammatory changes associated with COVID-19. This review highlights the current state of knowledge of the utility of
PrintDisplayed: 23/7/2024 21:18